Obama Announces National Strategic Computing InitiativeJul 30
|
Bio-IT World Brief | Yesterday President Obama has signed an executive order creating the National Strategic Computing Initiative. The Initiative aims to bring together several government agencies including the Department of Energy, Department of Defense, and the National Science Foundation to pursue exascale computing.
more

July News and Product BriefsJul 29
|
Bio-IT World | News and product briefs from around the industry, including Deep Genomins' DNA binding analytics and White House announcements about the Precision Medicine Initiative.
more

Biogen Looks Vulnerable After Stock Sell-OffJul 28
|
BostonGlobe.com | Cambridge biotechnology giant
Biogen Inc. may have to make a bold move to reassure investors --
buying back shares or snapping up a smaller company -- or it could
become a takeover target itself, some analysts warned Monday.
more

KeyGene and GENALICE report significant mutual benefits of their partnershipJul 15
|
HARDERWIJK, NETHERLANDS - Jul 15, 2015 - Today, molecular
genetics Ag Biotech company KeyGene and biomedical big data
solutions company GENALICE, jointly mark the significant mutual
benefits of their first two years of partnerships, running GENALICE
MAP in full production as their preferred tool for primary
Next-Generation Sequencing (NGS) data analysis more

Qlucore announces 3 year license from Europe's largest biopharmaceutical companyJul 15
|
LUND, SWEDEN - Jul 15, 2015 - ~~Qlucore announces 3 year
license from Europe's largest biopharmaceutical company
Software to help Actelion visualize and analyze "big data"
Qlucore, a world leader in the development of bioinformatics
software, has announced a three year license contract with
Actelion, one of Europe's leading biopharmaceutical companies
more

Clinical Conductor CTMS Release Targets Precise, Accurate Research ManagementJul 14
|
ROCHESTER, NY, UNITED STATES - Jul 14, 2015 - The latest iteration of Clinical Conductor CTMScontinues the proven strategy of providing research organizations with the most in-depth features and functionality available, further distancing the application from others in the industry, which fail to provide the tools necessary for truly complete clinical research management
more

EDGC and DIAGNOMICS SIGN AS INITIAL CUSTOMER FOR MAVERIX Dx PLATFORMJul 07
|
SAN MATEO, CA - Jul 7, 2015 - Maverix Biomics, Inc. today announced that EDGC (the Eone-Diagnomics Genome Center), a joint venture between an affiliate of the Eone Life Science Institute and Diagnomics, signed a contract to be the initial diagnostic testing customer on the Maverix Dx Platform
more

As data volumes grow and scientific advances require more compute power, life sciences organizations need more powerful, lower-cost solutions to meet demand. IBM Software Defined Infrastructure (SDI) featuring IBM® Platform Computing™ helps clients increase their competitive advantage by using an agile, high-performance, shared infrastructure resulting in faster time-to-results for analytics and collaboration across the research and development ecosystem.

IBM® is a global technology company that develops and sells software and systems including a broad range of infrastructure, IBM SoftLayer®cloud and consulting services in more than 170 countries. Along with its life sciences industry partners, IBM enables its clients to accelerate time-to-value with powerful IBM Power® and storage systems designed to accelerate and optimize life science workloads.

Exxact Certified Life Science GPU Systems
Exxact designs a series of certified life science GPU systems in collaboration with life science software developers to provide value-add turnkey solutions for optimizing the scientific workflow and accelerating the pace of research. Each system is ready to run out of the box and capable of accelerating complex bioscience codes, in fields encompassing, drug discovery, biocatalyst design, molecular biology, bioinformatics and materials science.

November 13 at 11am EST | Register Today to Reserve Your Space Sponsored by It is no surprise that authors place what they consider to be their most important and promising findings into an abstract. But as an abstract’s size